To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: Anti-Glycan Antibodies Show Diagnostic Utility in Paediatric Patients: Presented at UEGW URL: http://www.pslgroup.com/dg/216BA2.htm Doctor's Guide November 5, 2007
By Jill Stein PARIS, FRANCE -- November 5, 2007 -- Anti-glycan antibodies can help distinguish between Crohn's disease and ulcerative colitis in children, researchers announced here at the 15th United European Gastroenterology Week (UEGW).
Nir Dotan, PhD, researcher, Glycominds Ltd., Lod, Israel, and colleagues elsewhere assessed the diagnostic relevance of serological anti-glycan antibodies in 110 inflammatory bowel disease (IBD) patients <18 years and 630 patients >18 years at the time of blood sampling.
"Differentiation between Crohn's disease and ulcerative colitis in paediatric inflammatory bowel disease is often difficult due to overlapping clinical features," Dr. Dotan pointed out. "However, diagnosis is essential for the optimal choice of therapeutic options."
While paediatric patients may undergo invasive examination of combined upper endoscopy, colonoscopy, and terminal ileoscopy with biopsies, 5% to 30% of patients are still defined as "indeterminate colitis" or unclassified inflammatory bowel disease. The panel of serological anti-glycan antibodies IBDX has been found to aid in the differentiation between Crohn's disease and ulcerative colitis in adult patients, he continued. It seems highly likely that IBDX markers may also assist the physician in the diagnosis of paediatric IBD patients and potentially decrease the use of invasive examination in this sensitive population. In the trial, the diagnosis of IBD for each patient was based upon standard endoscopic, histologic, and radiographic criteria. Blinded serological analysis of antibodies against mannan epitope of Saccharomyces cerevisiae (gASCA), laminaribioside (ALCA), chitobioside (ACCA), and mannobioside (AMCA) were performed using IBDX ELISA panel (also made by Glycominds Ltd.).
Paediatric IBD patients, positive for at least one of the markers could be identified as CD patients with a sensitivity of 65% and specificity of 84%; the positive and negative predictive values were 91% and 50%, respectively. Patients positive for 2 or more markers could be identified as CD with higher specificity (94%) but lower sensitivity (22%).
No significant differences in the seroprevalence of anti-glycan antibodies were found between paediatric and adult IBD.
"The present study demonstrates for the first time that similar to adults, anti-glycan antibodies can distinguish between Crohn's disease and ulcerative colitis in a paediatric IBD population," Dr. Dotan said.
He added that future studies will further investigate the diagnostic ability of this noninvasive exam in additional paediatric patient cohorts in order to confirm the present results and explore the prognostic and disease management utility of the IBDX panel. [Presentation Title: Anti-Glycan Antibody Markers are Useful for Differentiation Between Crohn's Disease And Ulcerative Colitis in Children. Abstract G-250] --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.